Atractylodes regulates ROS/AKT signaling pathway to induce apoptosis and cycle arrest in endometrial cancer cells
10.3760/cma.j.cn115807-20250124-00040
- VernacularTitle:苍术素调控ROS/AKT信号通路诱导子宫内膜癌细胞凋亡的研究
- Author:
Yun ZHANG
1
;
Rui HUANG
1
;
Xu SHAO
1
;
Yan LI
1
Author Information
1. 山西省儿童医院 山西省妇幼保健院妇科，太原 030000
- Publication Type:Journal Article
- Keywords:
Atractylodes;
Reactive oxygen species;
Endometrial cancer;
Apoptosis;
AKT signal passway
- From:
Chinese Journal of Endocrine Surgery
2025;19(5):754-757
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the mechanism by which atractylodin regulates the ROS (reactive oxygen species) /AKT signaling pathway to induce apoptosis and cell cycle arrest in endometrial cancer cells, and to provide theoretical support for its potential application in the treatment of endometrial cancer.Methods:Endometrial cancer cell lines (Ishikawa and HEC-1A) were selected as experimental models. Cells were treated with different concentrations (1, 5, 10, 20 μM) of atractylodin. Cell proliferation was assessed by CCK-8 assay, apoptosis was analyzed by flow cytometry (FCM), and protein expression levels of AKT, p-AKT, Bcl-2, Caspase-3, and other AKT signaling pathway-related proteins were detected by Western blot. ROS levels were measured by flow cytometry.Results:Atractylodin treatment significantly inhibited the proliferation of endometrial cancer cells. Flow cytometry analysis revealed a marked increase in the apoptotic cell population. Western blot results showed that atractylodin treatment significantly decreased p-AKT expression, reduced Bcl-2 protein levels, and increased Caspase-3 expression. ROS level analysis showed that atractylodin treatment significantly elevated intracellular ROS generation, suggesting that atractylodin might induce AKT pathway inhibition through ROS, leading to cell cycle arrest and apoptosis.Conclusions:Atractylodin regulates the ROS/AKT signaling pathway to induce apoptosis and cell cycle arrest in endometrial cancer cells, exhibiting potential anti-endometrial cancer effects. This study provides new theoretical evidence for the application of atractylodin in the treatment of endometrial cancer and reveals its underlying mechanisms.
